ELAN - Elanco Animal Health Incorporated

NYSE - NYSE Delayed Price. Currency in USD
33.35
-0.33 (-0.98%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close33.68
Open33.68
Bid0.00 x 1200
Ask33.40 x 1300
Day's Range33.25 - 33.90
52 Week Range28.00 - 37.61
Volume1,467,429
Avg. Volume3,177,785
Market Cap12.196B
Beta (3Y Monthly)N/A
PE Ratio (TTM)243.43
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire20 days ago

    Elanco Announces R&D Collaboration with AgBiome for Swine Nutritional Health Innovation

    Elanco Animal Health Incorporated (ELAN), announced today a new global R&D collaboration with AgBiome, Inc. to develop nutritional health products for swine. The collaboration further demonstrates Elanco’s commitment to antibiotic stewardship and bringing alternatives to producers’ most difficult challenges.

  • Business Wire2 months ago

    New Study Suggests Service Dogs Can Impact Psychosocial Health of Household

    New data published in The American Journal of Occupational Therapy suggests the impact of a service dog may extend beyond the recipient and have positive impacts on family members as well. This study, funded by Elanco Animal Health Incorporated (ELAN) and conducted by Purdue University College of Veterinary Medicine, is the first of its kind using standardized measures to examine the relationship between the human animal bond and psychosocial outcomes among people with service dogs.

  • Business Wire2 months ago

    Elanco Animal Health Reports First Quarter Results

    GREENFIELD, Ind.-- -- Gross margin improved 190 basis points to 53.0 percent of revenue Earnings per share was $0.09 , or $0.25 Revenue declined 1 percent to $731.1 million; Total and Core Revenue both grew 2 percent at constant currency rates Revenue from Innovation portfolio grew 59 percent, represents 13 percent of total revenue Announced agreement to acquire Aratana Therapeutics and collaboration ...

  • Business Wire2 months ago

    Elanco Appoints Art A. Garcia to Board of Directors

    Elanco Animal Health (ELAN) today announced the appointment of Art A. Garcia, recently retired executive vice president and chief financial officer of Ryder System Inc., to the Board of Directors. The board was established in September 2018 when Elanco became a publicly traded company following its separation from Eli Lilly and Company.

  • GlobeNewswire3 months ago

    MERGER ALERT – PETX and SRMC: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies

    NEW YORK, April 30, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on.

  • GlobeNewswire3 months ago

    Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Aratana Therapeutics, Inc. (PETX) on Behalf of Stockholders and Encourages PETX Investors to Contact the Firm

    NEW YORK, April 29, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Aratana Therapeutics, Inc. (NASDAQ: PETX) on.

  • Business Wire3 months ago

    Elanco Confirms Date and Conference Call for First Quarter 2019 Financial Results Announcement

    Elanco Animal Health (ELAN) will announce its first quarter 2019 financial results on Thursday, May 9, 2019. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance. The conference call will begin at 8:00 a.m. Eastern time.

  • GlobeNewswire3 months ago

    QTNA, PETX, and SFS SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers

    WILMINGTON, Del., April 29, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: Quantenna Communications, Inc. (NYSE: QTNA) regarding possible breaches.

  • GlobeNewswire3 months ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Aratana Therapeutics, Inc. to Elanco Animal Health Incorporated is Fair to Shareholders

    NEW YORK, April 29, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Aratana Therapeutics, Inc..

  • PR Newswire3 months ago

    ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Aratana Therapeutics, Inc.

    NEW YORK , April 26, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Aratana Therapeutics, Inc. (NASDAQ: PETX) and its board of directors for breach of fiduciary duty concerning ...

  • Business Wire3 months ago

    Elanco Announces Agreement to Acquire Aratana Therapeutics; Completes Oncology Development Agreement with VetDC, Creates Specialty Veterinary Business Focus

    Elanco Animal Health (ELAN) today announced it has signed an agreement to acquire Aratana Therapeutics (PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, and developer of the first-of-its-kind canine NSAID for osteoarthritis, Galliprant®. Elanco has also signed a development and commercialization agreement with VetDC for Tanovea®-CA1, the first U.S. Food and Drug Administration (FDA) conditionally approved canine lymphoma treatment. In conjunction with these agreements, Elanco also announced the formation of a commercial team dedicated to the veterinary specialty business focused on bringing new and innovative products to the growing veterinary specialty category.

  • PR Newswire3 months ago

    Aratana Therapeutics to be Acquired by Elanco Animal Health

    LEAWOOD, Kan., April 26, 2019 /PRNewswire/ -- Aratana Therapeutics (PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, announced it has signed an agreement to be acquired by Elanco Animal Health (ELAN), its global collaboration partner on GALLIPRANT® (grapiprant tablets). In conjunction with the transaction, Elanco also announced the formation of a commercial team dedicated to the veterinary specialty business. Aratana's field force has demonstrated the ability to technically communicate with veterinarians on pet therapeutics and if the proposed agreement is consummated, the Aratana field force would transition into this commercial team.

  • Lilly Announces Final Results of Elanco Exchange Offer
    PR Newswire4 months ago

    Lilly Announces Final Results of Elanco Exchange Offer

    INDIANAPOLIS, March 13, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced the final results of its offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (ELAN) previously owned by Lilly, which expired at 12:00 midnight, New York City time, at the end of the day on March 8, 2019. Because the exchange offer was oversubscribed, Lilly accepted only a portion of the shares of its common stock that were validly tendered and not validly withdrawn, on a pro rata basis in proportion to the number of shares tendered. Shareholders who owned fewer than 100 shares of Lilly common stock, or an "odd-lot," who validly tendered all of their shares, were not subject to proration, in accordance with the terms of the exchange offer.

  • Business Wire4 months ago

    Elanco Appoints Four New Members to Board of Directors

    Elanco Animal Health Incorporated (ELAN) today announced the appointment of four new members to the Board of Directors. The Board was initially established in September 2018 when Elanco became a publicly traded company following its separation from Eli Lilly and Company. The appointments follow Lilly’s full divestiture of Elanco, making Elanco a fully independent company.

  • Business Wire4 months ago

    Elanco Animal Health Completes Separation from Lilly

    Elanco Animal Health Incorporated (ELAN) today announced that it is now a fully independent company. The completion of Eli Lilly and Company’s exchange offer completes the journey Elanco began in 2017 when its former parent company first announced the exploration of potential strategic alternatives for the 64-year-old animal health company. The exchange offer was 7.6x oversubscribed.

  • Lilly Announces Preliminary Results of Elanco Exchange Offer
    PR Newswire4 months ago

    Lilly Announces Preliminary Results of Elanco Exchange Offer

    INDIANAPOLIS, March 11, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced that, based on preliminary results, its previously-announced offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (ELAN) owned by Lilly was oversubscribed. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on March 8, 2019. Under the terms of the exchange offer, 4.5121 shares of Elanco common stock will be exchanged for each share of Lilly common stock accepted in the exchange offer.

  • Lilly Announces Final Exchange Ratio of 4.5121 for Elanco Exchange Offer
    PR Newswire4 months ago

    Lilly Announces Final Exchange Ratio of 4.5121 for Elanco Exchange Offer

    INDIANAPOLIS, March 7, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced the final exchange ratio for its previously-announced offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (ELAN) owned by Lilly. For each share of Lilly common stock that is validly tendered and not validly withdrawn by shareholders and that is accepted pursuant to the exchange offer, Lilly will deliver 4.5121 shares of Elanco common stock to or at the direction of any such tendering shareholder.

  • Business Wire5 months ago

    Elanco Animal Health to File Registration Statement in Connection With Lilly Divestiture Announcement

    Elanco Animal Health Incorporated (ELAN), formerly the animal health business of Eli Lilly and Company (Lilly), today announced it intends to file a Form S-4 Registration Statement with the Securities and Exchange Commission (SEC) in connection with Lilly’s proposed exchange offer whereby Lilly shareholders can exchange shares of Lilly common stock for shares of Elanco common stock owned by Lilly. The exchange offer is anticipated to be tax-free for participating Lilly shareholders in the United States, except with respect to cash received in lieu of fractional shares.

  • Lilly Will Initiate Divestiture of its Remaining Interest in Elanco Animal Health
    PR Newswire5 months ago

    Lilly Will Initiate Divestiture of its Remaining Interest in Elanco Animal Health

    INDIANAPOLIS, Feb. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) announced it will initiate an exchange offer today to divest its remaining interest in Elanco Animal Health (ELAN). Elanco completed its initial public offering (IPO) in September 2018, with Lilly retaining an 80.2 percent ownership interest in Elanco. In the exchange offer, Lilly shareholders can exchange all, some or none of their shares of Lilly common stock for shares of Elanco common stock owned by Lilly, subject to possible proration as described below.

  • Business Wire5 months ago

    Elanco Animal Health Reports Strong 2018 Fourth Quarter and Full Year Results, Confirms 2019 Guidance

    Full year global revenue increased 6 percent to $3.1 billion, Interceptor® Plus reaches blockbuster status with more than $100 million in annual sales

  • Business Wire6 months ago

    Elanco Revises Date for Fourth Quarter 2018 Financial Results

    Elanco Animal Health (ELAN) has revised the date for its fourth-quarter and full-year 2018 financial results announcement. Elanco will also conduct a conference call with the investment community and media on that day to further detail the company's financial performance. Elanco (ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries.

  • Elanco Animal Health and Performance Livestock Analytics Establish Data Service Agreement
    Business Wire6 months ago

    Elanco Animal Health and Performance Livestock Analytics Establish Data Service Agreement

    Performance Livestock Analytics, Inc. and Elanco Animal Health Incorporated , today announce an agreement to provide joint customers data from PLA’s fast-growing Performance Beef TM platform and access to Elanco’s Benchmark ® service.

  • Business Wire7 months ago

    Elanco Announces 2019 Financial Guidance

    Earnings per share (EPS) for 2019 are expected to be in the range of $0.36 to $0.48 on a reported basis and $1.02 to $1.12 on an adjusted basis. The company now expects 2018 EPS to be in the range of $0.15 to $0.17 on a reported basis. On an adjusted basis, the company reaffirms its expectation for 2018 EPS to be in the range of $1.14 to $1.16.

  • Business Wire7 months ago

    Elanco Animal Health Confirms Date and Conference Call for 2019 Financial Guidance

    Elanco Animal Health Incorporated (ELAN) will announce its financial guidance for 2019 on Tuesday, Dec. 18, 2018. Elanco will also conduct a conference call that day with the investment community to further detail the company's financial guidance. The conference call will begin at 8:00 a.m. Eastern time.

  • Business Wire8 months ago

    Elanco Animal Health and Farm Radio International Partner to Drive Change for Small-Scale Livestock Farmers in North Tanzania

    Elanco Animal Health Incorporated (ELAN) and Farm Radio International (FRI) have partnered to produce a 13-week series of radio programs designed to support and educate small-scale livestock farmers in North Tanzania to manage the challenges around livestock health and wellbeing, supporting a drive to greater food security, livestock health and care in the region. FRI and Elanco are working closely with local radio stations - Sauti ya Injili and Loliondo FM - to produce a short series of interactive radio programs, enabling listeners to make informed decisions, and have access to relevant animal health care products and training.